These results suggest the potential for timely and proactive interventions targeting modifiable risk factors, such as measuring plasma KLK1 concentrations in individuals with MetS and stroke, to mitigate stroke risk and recurrence, thereby enhancing outcomes in cerebrovascular disease management. Here, KLK1 is linked to metabolic syndrome.